Skip to content
Study details
Enrolling now

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

National Institute of Allergy and Infectious Diseases (NIAID)
NCT IDNCT06504160ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

86

Study length

about 1.6 years

Ages

12+

Locations

8 sites in CA, CO, IL +3

What this study is about

This trial is testing a treatment for atopic dermatitis. It compares ShA9 topical gel to placebo, and also looks at the safety of ShA9 when used with topical corticosteroids.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Clobetasol Ointment
  • 2.Take Fluocinonide Ointment
  • 3.Take Hydrocortisone Ointment
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
topicaltopical

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

clobetasol, CARDIOVASCULAR SYSTEM, hydrocortisone

Drug routes

topical, injection (Injection)

Endpoints

Primary: Serious and non-serious treatment-emergent adverse events (TEAEs) related or possibly related to study treatment.

Secondary: Change in Pruritus Numeric Rating Scale (NRS) score., Serious and non-serious TEAEs related or possibly related to study treatment.

Body systems

Dermatology